Significance: In this study, we show for the first time, to our knowledge, that Muscleblind-like 3 (MBNL3) down-regulation in therapy-resistant human blast crisis leukemia stem cells (LSCs) is associated with activation of a human embryonic stem cell alternative splicing gene regulatory network involved in reprogramming and expression of a CD44 splice isoform, CD44 transcript variant 3. Targeting blast crisis LSCs with a human CD44 monoclonal antibody in combination with a potent breakpoint cluster region - ABL proto-oncogene 1, nonreceptor tyrosine kinase (BCR-ABL1) antagonist impairs LSC self-renewal in a niche-dependent manner and provides a compelling rationale for devising novel clinical combination LSC eradication strategies.
While implicated in therapeutic resistance, malignant progenitor cell cycle kinetics have been difficult to quantify in real-time. We developed an efficient lentiviral bicistronic fluorescent, ubiquitination-based cell cycle indicator reporter (Fucci2BL) to image live single progenitors on a defined niche coupled with cell cycle gene expression analysis. We have identified key differences in cell cycle regulatory gene expression and transit times between normal and chronic myeloid leukemia progenitors that may inform cancer stem cell eradication strategies.